title: Papulopustular eruption after intravitreal bevacizumab (Avastin).
authors.forename: Luis
authors.initials: L
authors.lastname: Amselem
authors.forename: Manuel
authors.initials: M
authors.lastname: Diaz-Llopis
authors.forename: Salvador
authors.initials: S
authors.lastname: Garcia-Delpech
authors.forename: Javier
authors.initials: J
authors.lastname: Montero
authors.forename: Paula
authors.initials: P
authors.lastname: Palomares
authors.forename: Enrique
authors.initials: E
authors.lastname: Cervera
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab